ArticleAnnals of surgical oncology2026
Impact of Machine Perfusion on Liver Transplantation for Hepatocellular Carcinoma.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIschemic reperfusion injury (IRI) during liver transplantation is associated with recurrence of hepatocellular carcinoma (HCC). Machine perfusion (MP) is associated with a decreased risk of IRI complications. Our study evaluated the role of MP in post-transplant oncologic outcomes in patients with HCC.
methodsAdults with HCC transplanted between 2015-2025 from the United Network for Organ Sharing database were divided into MP and no-MP groups. Propensity score matching (PSM) was also performed. Post-transplant HCC recurrence (competing risk) and overall survival (OS) were assessed. Subgroup analysis was performed in populations within and beyond the Milan criteria.
resultsA total of 19,466 patients were included in this study. MP was used in 1,392 (7.2%). The MP group had shorter waitlist times, older donors, and more frequent DCDs (p=0.001). After PSM, 512 patients were included in each group (336 patients within Milan criteria in each). In the population beyond Milan after PSM (n=352), MP use was associated with a reduced risk of 1-year and 3-year HCC recurrence (adjusted hazard ratio (aHR) 0.09, p=0.02; aHR 0.27, p=0.02). MP use was not associated with the 1-year or 3-year OS (aHR 1.34, p=0.64; aHR 1.32, p=0.54).
conclusionsMP may potentially reduce the risk of HCC recurrence in recipients beyond Milan criteria, without significant difference in OS. However, as MP utilization increases, further validation into the role of MP and oncologic outcomes in larger cohort studies are required.
Indexed as
Identifiers
42886321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.